We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01475331
Recruitment Status : Completed
First Posted : November 21, 2011
Last Update Posted : March 10, 2017
Information provided by (Responsible Party):
Matthew T. Moyer, Milton S. Hershey Medical Center

November 8, 2011
November 21, 2011
March 10, 2017
November 2011
January 2017   (Final data collection date for primary outcome measure)
Change in cyst volume [ Time Frame: 3, 6, and 12 months post procedure ]
The primary outcome of interest will be change in cyst size, as measured on initial, 3, 6, and 12 month CT/MRI, or as determined necessary to evaluate cyst resolution
Same as current
Complete list of historical versions of study NCT01475331 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts
Not Provided
The purpose of this study is to evaluate the efficacy of a chemotherapeutic cocktail with or without prior ethanol lavage for ablation of premalignant pancreatic cysts using endoscopic ultrasound-guided fine needle injection (EUS-FNI) for agent delivery.

While about half of pancreatic cystic lesions have little to no malignant potential, mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) carry a high potential for progression into pancreatic cancer. Therefore, either close radiographic surveillance or surgical resection is generally recommended for these cysts. However, pancreatic surgery is associated with a significant risk of morbidity and mortality and not all patients are good surgical candidates. As an alternative, endoscopic ultrasound-guided fine needle injection(EUS-FNI) has been shown to be moderately effective in ablating cystic lesions.

The goal of this investigation is to improve the efficacy and safety of this procedure when compared with previous versions of the technique. This study is designed to evaluate the efficacy of a chemotherapeutic cocktail with or without prior ethanol lavage for ablation of pancreatic cystic neoplasms using EUS-FNI for agent delivery. This paired, prospective, double-blind, randomized study will include 78 patients referred to the Penn State Hershey Medical Center. Mucinous or indeterminate pancreatic cysts of 1-5cm with less than 5 compartments and without clear communication with the main pancreatic duct will be included. Patients will be randomized in a 1:1 ratio into a control arm or study arm. Patients randomized to the control arm will receive ethanol lavage of the cyst followed by injection of two carefully selected chemotherapeutic agents. Study arm patients will receive a normal saline lavage followed by injection of the same chemotherapy admixture. Patients will be monitored for 2 hours post-procedure, and a follow-up CT will be performed at 3, 6, and 12 months, or as determined necessary to evaluate cyst resolution. Patients may elect to undergo evaluation for surgical resection at any time, regardless of response, in which case a dedicated pathologist will evaluate any surgical specimens.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Mucinous Pancreatic Cysts
  • Drug: Ethanol
    Cysts will be lavaged for 3-5 minutes with 80% EtOH
  • Drug: Normal Saline
    Cysts will be lavaged for 3-5 minutes with normal saline
  • Drug: Chemotherapy
    Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
  • Active Comparator: Control Group
    • Drug: Ethanol
    • Drug: Chemotherapy
  • Experimental: Study Group
    • Drug: Normal Saline
    • Drug: Chemotherapy
Moyer MT, Sharzehi S, Mathew A, Levenick JM, Headlee BD, Blandford JT, Heisey HD, Birkholz JH, Ancrile BB, Maranki JL, Gusani NJ, McGarrity TJ, Dye CE. The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol. Gastroenterology. 2017 Nov;153(5):1295-1303. doi: 10.1053/j.gastro.2017.08.009. Epub 2017 Aug 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
January 2017
January 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients age 18 and older of any gender, ethnicity and race
  • Voluntary enrollment and ability to give written informed consent
  • Capable of safely undergoing endoscopy with deep sedation or general anesthesia
  • Patients with previously-detected pancreatic cyst(s) 1-5 cm in diameter, including indeterminate cysts

Exclusion Criteria:

  • Pancreatic cyst <1cm or >5cm
  • Pancreatic cyst with clear communication with main pancreatic duct
  • Clearly benign lesions by clinical and radiographic evaluation (pseudocysts and serous cystadenomas)
  • Known or suspected pancreatic cancer or pathologic lymphadenopathy
  • Septated cysts with > 5 compartments
  • Coagulopathy (international normalized ratio > 1.6, platelets < 30,000)
  • Evidence of active pancreatitis or pancreatic infection
  • Patients having undergone endoscopic retrograde cholangiopancreatography (ERCP) within 72 hours
  • Baseline lab values at the time of consent: white blood cells > 14 or < 2, hematocrit < 30, platelets < 30,000, INR > 1.6, abnormal CA19-9, lipase > 3 times the upper limit of normal, creatinine > 2.5, ALT > 210, total bilirubin > 2.5, positive qualitative beta-hCG.
  • Any pre-existing or discovered medical condition that may, at the discretion of the investigator, interfere with the completion of and/or participation in the existing protocol.
  • Pregnant, breastfeeding, or incarcerated individuals
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
IRB 33751
Not Provided
Not Provided
Matthew T. Moyer, Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Not Provided
Not Provided
Milton S. Hershey Medical Center
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP